Interleukin-6  ||| S:0 E:14 ||| FW
attenuates  ||| S:14 E:25 ||| FW
serotonin  ||| S:25 E:35 ||| FW
2a  ||| S:35 E:38 ||| FW
receptor  ||| S:38 E:47 ||| FW
signaling  ||| S:47 E:57 ||| FW
by  ||| S:57 E:60 ||| IN
activating  ||| S:60 E:71 ||| VBG
the  ||| S:71 E:75 ||| DT
JAK-STAT  ||| S:75 E:84 ||| JJ
pathway  ||| S:84 E:92 ||| NNS
The  ||| S:92 E:96 ||| DT
serotonin  ||| S:96 E:106 ||| JJ
2A  ||| S:106 E:109 ||| NNP
( ||| S:109 E:110 ||| -LRB-
5-HT2A ||| S:110 E:116 ||| NNP
)  ||| S:116 E:118 ||| -RRB-
receptor  ||| S:118 E:127 ||| NN
and  ||| S:127 E:131 ||| CC
the  ||| S:131 E:135 ||| DT
proinflammatory  ||| S:135 E:151 ||| JJ
cytokine ||| S:151 E:159 ||| NN
,  ||| S:159 E:161 ||| ,
interleukin-6  ||| S:161 E:175 ||| NNP
( ||| S:175 E:176 ||| -LRB-
IL-6 ||| S:176 E:180 ||| NNP
) ||| S:180 E:181 ||| -RRB-
,  ||| S:181 E:183 ||| ,
have  ||| S:183 E:188 ||| VBP
both  ||| S:188 E:193 ||| DT
been  ||| S:193 E:198 ||| VBN
implicated  ||| S:198 E:209 ||| VBN
in  ||| S:209 E:212 ||| IN
psychiatric  ||| S:212 E:224 ||| JJ
disorders ||| S:224 E:233 ||| NNS
.  ||| S:233 E:235 ||| .
Previously ||| S:235 E:245 ||| RB
,  ||| S:245 E:247 ||| ,
we  ||| S:247 E:250 ||| PRP
demonstrated  ||| S:250 E:263 ||| VBD
that  ||| S:263 E:268 ||| IN
these  ||| S:268 E:274 ||| DT
molecules  ||| S:274 E:284 ||| NNS
both  ||| S:284 E:289 ||| CC
facilitate  ||| S:289 E:300 ||| VB
cognitive  ||| S:300 E:310 ||| JJ
flexibility ||| S:310 E:321 ||| NN
,  ||| S:321 E:323 ||| ,
a  ||| S:323 E:325 ||| DT
prefrontal  ||| S:325 E:336 ||| JJ
cortex-mediated  ||| S:336 E:352 ||| JJ
executive  ||| S:352 E:362 ||| NN
function  ||| S:362 E:371 ||| VBP
impaired  ||| S:371 E:380 ||| VBN
in  ||| S:380 E:383 ||| IN
multiple  ||| S:383 E:392 ||| JJ
mental  ||| S:392 E:399 ||| JJ
illnesses ||| S:399 E:408 ||| NNS
.  ||| S:408 E:410 ||| .
In  ||| S:410 E:413 ||| IN
this  ||| S:413 E:418 ||| DT
study ||| S:418 E:423 ||| NN
,  ||| S:423 E:425 ||| ,
we  ||| S:425 E:428 ||| PRP
tested  ||| S:428 E:435 ||| VBD
the  ||| S:435 E:439 ||| DT
hypothesis  ||| S:439 E:450 ||| NN
that  ||| S:450 E:455 ||| IN
IL-6  ||| S:455 E:460 ||| FW
influences  ||| S:460 E:471 ||| FW
5-HT2A  ||| S:471 E:478 ||| FW
receptor  ||| S:478 E:487 ||| FW
signaling ||| S:487 E:496 ||| FW
,  ||| S:496 E:498 ||| ,
providing  ||| S:498 E:508 ||| VBG
a  ||| S:508 E:510 ||| DT
potential  ||| S:510 E:520 ||| JJ
mechanism  ||| S:520 E:530 ||| NN
by  ||| S:530 E:533 ||| IN
which  ||| S:533 E:539 ||| WDT
this  ||| S:539 E:544 ||| DT
cytokine  ||| S:544 E:553 ||| NN
may  ||| S:553 E:557 ||| MD
influence  ||| S:557 E:567 ||| VB
behavior ||| S:567 E:575 ||| NN
.  ||| S:575 E:577 ||| .
We  ||| S:577 E:580 ||| PRP
first  ||| S:580 E:586 ||| RB
demonstrated  ||| S:586 E:599 ||| VBN
that  ||| S:599 E:604 ||| IN
5-HT2A  ||| S:604 E:611 ||| CD
receptors  ||| S:611 E:621 ||| NNS
and  ||| S:621 E:625 ||| CC
IL-6-mediated  ||| S:625 E:639 ||| CD
STAT3  ||| S:639 E:645 ||| CD
phosphorylation  ||| S:645 E:661 ||| JJ
colocalize  ||| S:661 E:672 ||| NN
in  ||| S:672 E:675 ||| IN
cells  ||| S:675 E:681 ||| NNS
of  ||| S:681 E:684 ||| IN
the  ||| S:684 E:688 ||| DT
prefrontal  ||| S:688 E:699 ||| JJ
cortex ||| S:699 E:705 ||| NN
,  ||| S:705 E:707 ||| ,
providing  ||| S:707 E:717 ||| VBG
the  ||| S:717 E:721 ||| DT
neuroanatomical  ||| S:721 E:737 ||| JJ
substrate  ||| S:737 E:747 ||| NN
for  ||| S:747 E:751 ||| IN
a  ||| S:751 E:753 ||| DT
potential  ||| S:753 E:763 ||| JJ
interaction ||| S:763 E:774 ||| NN
.  ||| S:774 E:776 ||| .
In  ||| S:776 E:779 ||| IN
the  ||| S:779 E:783 ||| DT
neuronally  ||| S:783 E:794 ||| NN
derived  ||| S:794 E:802 ||| VBD
A1A1  ||| S:802 E:807 ||| CD
cell  ||| S:807 E:812 ||| NN
line ||| S:812 E:816 ||| NN
,  ||| S:816 E:818 ||| ,
which  ||| S:818 E:824 ||| WDT
expresses  ||| S:824 E:834 ||| VBZ
both  ||| S:834 E:839 ||| DT
IL-6  ||| S:839 E:844 ||| NNP
and  ||| S:844 E:848 ||| CC
5-HT2A  ||| S:848 E:855 ||| CD
receptors ||| S:855 E:864 ||| NNS
,  ||| S:864 E:866 ||| ,
we  ||| S:866 E:869 ||| PRP
found  ||| S:869 E:875 ||| VBD
that  ||| S:875 E:880 ||| IN
IL-6  ||| S:880 E:885 ||| FW
attenuates  ||| S:885 E:896 ||| FW
inositol  ||| S:896 E:905 ||| FW
phosphate  ||| S:905 E:915 ||| FW
( ||| S:915 E:916 ||| -LRB-
IP ||| S:916 E:918 ||| NNP
)  ||| S:918 E:920 ||| -RRB-
accumulation  ||| S:920 E:933 ||| NN
in  ||| S:933 E:936 ||| IN
response  ||| S:936 E:945 ||| NN
to  ||| S:945 E:948 ||| TO
the  ||| S:948 E:952 ||| DT
5-HT2  ||| S:952 E:958 ||| JJ
agonist ||| S:958 E:965 ||| NN
,  ||| S:965 E:967 ||| ,
2,5-dimethoxy-4-iodoamphetamine  ||| S:967 E:999 ||| NNP
( ||| S:999 E:1000 ||| -LRB-
DOI ||| S:1000 E:1003 ||| NNP
) ||| S:1003 E:1004 ||| -RRB-
,  ||| S:1004 E:1006 ||| ,
suggesting  ||| S:1006 E:1017 ||| VBG
that  ||| S:1017 E:1022 ||| IN
IL-6  ||| S:1022 E:1027 ||| NNP
can  ||| S:1027 E:1031 ||| MD
regulate  ||| S:1031 E:1040 ||| VB
5-HT2A  ||| S:1040 E:1047 ||| CD
receptor  ||| S:1047 E:1056 ||| NN
function ||| S:1056 E:1064 ||| NN
.  ||| S:1064 E:1066 ||| .
To  ||| S:1066 E:1069 ||| TO
identify  ||| S:1069 E:1078 ||| VB
the  ||| S:1078 E:1082 ||| DT
signaling  ||| S:1082 E:1092 ||| JJ
pathway ||| S:1092 E:1099 ||| NNS
( ||| S:1099 E:1100 ||| -LRB-
s ||| S:1100 E:1101 ||| LS
)  ||| S:1101 E:1103 ||| -RRB-
that  ||| S:1103 E:1108 ||| WDT
mediate  ||| S:1108 E:1116 ||| VBZ
this  ||| S:1116 E:1121 ||| DT
effect ||| S:1121 E:1127 ||| NN
,  ||| S:1127 E:1129 ||| ,
we  ||| S:1129 E:1132 ||| PRP
measured  ||| S:1132 E:1141 ||| VBD
DOI-mediated  ||| S:1141 E:1154 ||| NNP
IP  ||| S:1154 E:1157 ||| NNP
accumulation  ||| S:1157 E:1170 ||| NN
in  ||| S:1170 E:1173 ||| IN
the  ||| S:1173 E:1177 ||| DT
presence  ||| S:1177 E:1186 ||| NN
of  ||| S:1186 E:1189 ||| IN
IL-6  ||| S:1189 E:1194 ||| NNP
and  ||| S:1194 E:1198 ||| CC
either  ||| S:1198 E:1205 ||| RB
the  ||| S:1205 E:1209 ||| DT
JAK-STAT  ||| S:1209 E:1218 ||| JJ
inhibitor  ||| S:1218 E:1228 ||| NN
124  ||| S:1228 E:1232 ||| CD
[ ||| S:1232 E:1233 ||| CD
( ||| S:1233 E:1234 ||| -LRB-
9β ||| S:1234 E:1236 ||| NNP
, ||| S:1236 E:1237 ||| ,
10α ||| S:1237 E:1240 ||| NNP
, ||| S:1240 E:1241 ||| ,
16α ||| S:1241 E:1244 ||| NNP
, ||| S:1244 E:1245 ||| ,
23E ||| S:1245 E:1248 ||| CD
) ||| S:1248 E:1249 ||| -RRB-
-2,16,20,25-tetrahydroxy-9-methyl-19-norlanosta-1,5,23-triene-3,11,22-trione ||| S:1249 E:1325 ||| CD
] ||| S:1325 E:1326 ||| -RRB-
,  ||| S:1326 E:1328 ||| ,
JSI-124 ||| S:1328 E:1335 ||| NNP
,  ||| S:1335 E:1337 ||| ,
or  ||| S:1337 E:1340 ||| CC
the  ||| S:1340 E:1344 ||| DT
extracellular  ||| S:1344 E:1358 ||| JJ
signal-regulated  ||| S:1358 E:1375 ||| JJ
kinase  ||| S:1375 E:1382 ||| JJ
inhibitor ||| S:1382 E:1391 ||| NN
,  ||| S:1391 E:1393 ||| ,
2- ||| S:1393 E:1395 ||| NNP
( ||| S:1395 E:1396 ||| -LRB-
2-amino-3-methoxyphenyl ||| S:1396 E:1419 ||| NNP
) ||| S:1419 E:1420 ||| -RRB-
-4H-1-benzopyran-4-one  ||| S:1420 E:1443 ||| NNP
( ||| S:1443 E:1444 ||| -LRB-
PD-98059 ||| S:1444 E:1452 ||| NNP
) ||| S:1452 E:1453 ||| -RRB-
.  ||| S:1453 E:1455 ||| .
The  ||| S:1455 E:1459 ||| DT
IL-6  ||| S:1459 E:1464 ||| JJ
effect  ||| S:1464 E:1471 ||| NN
was  ||| S:1471 E:1475 ||| VBD
blocked  ||| S:1475 E:1483 ||| VBN
by  ||| S:1483 E:1486 ||| IN
JSI-124  ||| S:1486 E:1494 ||| NNP
but  ||| S:1494 E:1498 ||| CC
not  ||| S:1498 E:1502 ||| RB
PD-98059 ||| S:1502 E:1510 ||| CD
.  ||| S:1510 E:1512 ||| .
Furthermore ||| S:1512 E:1523 ||| RB
,  ||| S:1523 E:1525 ||| ,
silencing  ||| S:1525 E:1535 ||| VBG
RNA  ||| S:1535 E:1539 ||| NNP
knockdown  ||| S:1539 E:1549 ||| NN
of  ||| S:1549 E:1552 ||| IN
either  ||| S:1552 E:1559 ||| DT
JAK  ||| S:1559 E:1563 ||| NNP
or  ||| S:1563 E:1566 ||| CC
STAT  ||| S:1566 E:1571 ||| NNP
blocked  ||| S:1571 E:1579 ||| VBD
the  ||| S:1579 E:1583 ||| DT
IL-6  ||| S:1583 E:1588 ||| JJ
effect ||| S:1588 E:1594 ||| NN
,  ||| S:1594 E:1596 ||| ,
suggesting  ||| S:1596 E:1607 ||| VBG
that  ||| S:1607 E:1612 ||| IN
IL-6-induced  ||| S:1612 E:1625 ||| CD
JAK-STAT  ||| S:1625 E:1634 ||| JJ
activation  ||| S:1634 E:1645 ||| NN
can  ||| S:1645 E:1649 ||| MD
regulate  ||| S:1649 E:1658 ||| VB
5-HT2A  ||| S:1658 E:1665 ||| CD
receptor  ||| S:1665 E:1674 ||| NN
signaling ||| S:1674 E:1683 ||| NN
.  ||| S:1683 E:1685 ||| .
Finally ||| S:1685 E:1692 ||| RB
,  ||| S:1692 E:1694 ||| ,
to  ||| S:1694 E:1697 ||| TO
determine  ||| S:1697 E:1707 ||| VB
if  ||| S:1707 E:1710 ||| IN
IL-6  ||| S:1710 E:1715 ||| NNP
specifically  ||| S:1715 E:1728 ||| RB
regulates  ||| S:1728 E:1738 ||| VBZ
the  ||| S:1738 E:1742 ||| DT
5-HT2A  ||| S:1742 E:1749 ||| JJ
receptor  ||| S:1749 E:1758 ||| NN
system ||| S:1758 E:1764 ||| NN
,  ||| S:1764 E:1766 ||| ,
we  ||| S:1766 E:1769 ||| PRP
measured  ||| S:1769 E:1778 ||| VBD
IP  ||| S:1778 E:1781 ||| NNP
production  ||| S:1781 E:1792 ||| NN
mediated  ||| S:1792 E:1801 ||| NN
by  ||| S:1801 E:1804 ||| IN
another  ||| S:1804 E:1812 ||| DT
Gq-coupled  ||| S:1812 E:1823 ||| JJ
receptor ||| S:1823 E:1831 ||| NN
,  ||| S:1831 E:1833 ||| ,
bradykinin  ||| S:1833 E:1844 ||| JJ
B2 ||| S:1844 E:1846 ||| NN
.  ||| S:1846 E:1848 ||| .
IL-6  ||| S:1848 E:1853 ||| NNP
had  ||| S:1853 E:1857 ||| VBD
no  ||| S:1857 E:1860 ||| DT
effect  ||| S:1860 E:1867 ||| NN
on  ||| S:1867 E:1870 ||| IN
bradykinin-mediated  ||| S:1870 E:1890 ||| NNP
IP  ||| S:1890 E:1893 ||| NNP
accumulation ||| S:1893 E:1905 ||| NN
,  ||| S:1905 E:1907 ||| ,
suggesting  ||| S:1907 E:1918 ||| VBG
that  ||| S:1918 E:1923 ||| DT
regulation  ||| S:1923 E:1934 ||| NN
may  ||| S:1934 E:1938 ||| MD
occur  ||| S:1938 E:1944 ||| VB
at  ||| S:1944 E:1947 ||| IN
the  ||| S:1947 E:1951 ||| DT
5-HT2A  ||| S:1951 E:1958 ||| JJ
receptor ||| S:1958 E:1966 ||| NN
.  ||| S:1966 E:1968 ||| .
These  ||| S:1968 E:1974 ||| DT
results  ||| S:1974 E:1982 ||| NNS
may  ||| S:1982 E:1986 ||| MD
provide  ||| S:1986 E:1994 ||| VB
clues  ||| S:1994 E:2000 ||| NNS
to  ||| S:2000 E:2003 ||| TO
the  ||| S:2003 E:2007 ||| DT
pathologic  ||| S:2007 E:2018 ||| JJ
mechanisms  ||| S:2018 E:2029 ||| NNS
underlying  ||| S:2029 E:2040 ||| VBG
certain  ||| S:2040 E:2048 ||| JJ
psychiatric  ||| S:2048 E:2060 ||| JJ
disorders  ||| S:2060 E:2070 ||| NNS
and  ||| S:2070 E:2074 ||| CC
may  ||| S:2074 E:2078 ||| MD
suggest  ||| S:2078 E:2086 ||| VB
novel  ||| S:2086 E:2092 ||| JJ
therapeutic  ||| S:2092 E:2104 ||| JJ
strategies  ||| S:2104 E:2115 ||| NNS
for  ||| S:2115 E:2119 ||| IN
their  ||| S:2119 E:2125 ||| PRP$
treatment ||| S:2125 E:2134 ||| NN
.  ||| S:2134 E:2136 ||| .
